Vimarsana
Biggest News Aggregation in the World

Page 7 - B Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from B Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In B Cell Today - Breaking & Trending Today

Study suggests antibodies triggered by COVID-19 mRNA vaccination may depend on prior infection history - Vimarsana News

Study suggests antibodies triggered by COVID-19 mRNA vaccination may depend on prior infection history

Researchers evaluated distinct immune responses to mRNA and vector-based COVID-19 vaccines and natural SARS-CoV-2 infections.

Deep learning framework DeepAIR could improve understanding of adaptive immunity - Vimarsana News

Deep learning framework DeepAIR could improve understanding of adaptive immunity

Researchers presented a deep learning framework, DeepAIR, to accurately predict adaptive immune receptor (AIR)-antigen binding.

Novel multi-epitope subunit vaccine induces robust immune response against Epstein-Barr virus - Vimarsana News

Novel multi-epitope subunit vaccine induces robust immune response against Epstein-Barr virus

Scientists have developed a lymph node-targeted multi-epitope subunit vaccine that induces strong humoral and cellular immune responses against EBV in mice.

Researchers uncover genetic machinery responsible for EBV-induced B cell growth transformation - Vimarsana News

Researchers uncover genetic machinery responsible for EBV-induced B cell growth transformation

B cells or B lymphocytes are an important part of the body's immune system. When healthy B cells are infected with the Epstein-Barr virus (EBV), they undergo growth transformation, a process that immortalizes B cells, leading to their uncontrolled proliferation.

Novel approach: intranasal vaccination strategy targets Omicron COVID-19 variants - Vimarsana News

Novel approach: intranasal vaccination strategy targets Omicron COVID-19 variants

Researchers tested the efficacy of a two to three-dose intranasal (IN) regimen of the NDV-HXP-S vaccine.